$2.5m placement
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The placement is expected to generate significant interest from sophisticated investors, with commitments already received. Completion of the placement is subject to shareholder approval at an upcoming Extraordinary General Meeting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from AdAlta
- BZDS1901 manufacturing agreement
- Automated cell therapy manufacturing MoU
- BZDS1901 clinical update
- AdCella and SHcell hold first JDC meeting
- New AD-214 patent granted
Later from AdAlta
- Regulatory advisors appointed for BZDS1901
- Second BZDS1901 milestone paid
- Oktopi AI collaboration for research efficiency
- Quarterly Appendix 4C and Activities Report
- 2 year survival milestone for EW-001 patient
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta